Autopsy report · NCT00718640

An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function

“Study stopped due to lagging enrolment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months after it had already started.
• Ran for about 2 years 3 months before it stopped.
• 10 participants enrolled.
• Results were posted on the registry 3 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Janssen-Ortho Inc., Canada

Sponsor type

Industry

Conditions

Multiple Myeloma

Interventions

Dexamethasone; Bortezomib

Participants

10

Sites

5

Countries

Canada

Trials that died the same way

• OrthoPulse Gen 2 Initial Device Evaluation and Assessment of Clinical Effectiveness (CA)
  “Study stopped because slow enrolment.” (89% match in meaning)
• UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
  “Study stopped prematurely due to enrolment challenges.” (81% match in meaning)
• LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  “Study was terminated due to slow accrual.” (77% match in meaning)
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
  “Study stopped due to slow enrollment” (76% match in meaning)
• Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation
  “Study was stopped after interim analysis and slow enrollment.” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.